FeesSafety
Pluang+

Crossroads Gold reports high-grade gold soil results up to 24.6 g/t at Pambula, Australia, identifying new drill targets.

Market News
14 Sep 2026
TheNewswire
View Source
Bullish
Crossroads Gold reports high-grade gold soil results up to 24.6 g/t at Pambula, Australia, identifying new drill targets.

Crossroads Gold announced high-grade gold-in-soil assay results reaching up to 24.6 g/t from its 2026 exploration program at the Pambula Gold Project in southeastern Australia. Using LiDAR and soil geochemistry, the company identified multiple new drill targets, especially in the historic Hidden Treasure Zone, which has never been drilled before. These findings suggest a significant low-sulphidation epithermal gold system with strong potential for high-grade vein discoveries. Crossroads plans to prioritize these targets in upcoming drilling programs to assess the scale and continuity of the mineralization.

Crossroads Gold exploration results provide context for market activity. For readers following US stocks on Pluang, here is the market snapshot as of Sep 14, 2026 18:52 WIB: Out of 150 priced US stocks, 63 rose and 81 fell. Notable movers include AMD at USD 486.75 (-5.69%), ASX at USD 37.30 (-5.50%), and FCEL at USD 15.10 (-4.97%).

More News

Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...

Company Fundamentals
Bullish
48 minutes ago
Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...

Company Fundamentals
Bullish
48 minutes ago
AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker has introduced a comprehensive Business Class Flight Routes Guide to help travelers from the US explore premium flight options to 15 major international destinations across Asia, Europe, Africa, and Australia. The guide covers airlines, ...

Others
Neutral
3 hours ago
Ethereum co-founder predicts AI and crypto will merge to enable trusted automated work on blockchain.

Ethereum co-founder predicts AI and crypto will merge to enable trusted automated work on blockchain.

Joseph Lubin, co-founder of Ethereum, predicts that artificial intelligence (AI) and cryptocurrency will merge on the Ethereum blockchain to create a system where automated tasks are commissioned, completed, and paid for with trust guaranteed by bloc...

Protocol Fundamentals
Bullish
4 hours ago
Bitcoin dips near $80K amid lower trading volume and rising exchange reserves, signaling cautious market sentiment.

Bitcoin dips near $80K amid lower trading volume and rising exchange reserves, signaling cautious market sentiment.

Bitcoin's price dropped to around $80,494, down 1.26%, alongside a 14.11% decline in trading volume, indicating weaker market participation. Despite increased network activity and a slight rise in Bitcoin's market dominance, sentiment remained neutra...

Market News
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App